Sara S. Marelli
Biopharmaceuticals R&D, AstraZeneca
Cambridge, ENG CB20AA, United Kingdom
Cambridge, ENG CB20AA, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Sub-stoichiometric 5-methoxyuridine modification enables tunable immune evasion and protein expression from synthetic mRNAs.
Journal: Molecular therapy. Nucleic acids
Published: February 16, 2026
Defining Composition-Cytokine Relationships Enables the Design of Lipid Nanoparticles with Programmed Immunogenicity.
Journal: Small (Weinheim an der Bergstrasse, Germany)
Published: February 11, 2026
Correction for Kajaste-Rudnitski et al., "TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF-κB-Responsive Long Terminal Repeat Elements".
Journal: Journal of virology
Published: January 27, 2025
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.
Journal: Cell reports
Published: February 03, 2021
Anaphylaxis to nimesulide.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: October 17, 2020
Functional proteomic atlas of HIV infection in primary human CD4+ T cells.
Journal: eLife
Published: August 31, 2018
Herpesviruses shape tumour microenvironment through exosomal transfer of viral microRNAs.
Journal: PLoS pathogens
Published: March 17, 2017
Fission yeast Ccq1 is a modulator of telomerase activity.
Journal: Nucleic acids research
Published: March 16, 2017
HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter.
Journal: Retrovirology
Published: June 04, 2015
Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease.
Journal: AIDS (London, England)
Published: August 08, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026